There’s no question that eftilagimod works. It’s only a question of when to start it and what dosage. Long-term we could see approval, short term price will continue to fluctuate.
Marc can approach other big drug companies at conferences like Jeffries informally to see how interested they are in acquiring IMM.
The recent fundraising may have been driven by a failure of Merck to make an adequate offer. IMM can now continue to do business independently while it searches for better offers
New data later this year in first line treatment will show efficacy and survivability with minimal morbidity. I can see this becoming the treatment of choice for head and neck cancer.
There’s no question that eftilagimod works. It’s only a question...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $584.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 42.0¢ | 40.0¢ | $833.9K | 2.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 38358 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 105000 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
41.5¢ |
Change
0.000 ( 3.29 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 42.0¢ | 40.5¢ | 804683 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| IMM (ASX) Chart |